Related Experiment Video
Updated: Jul 13, 2026

Screening Ion Channels in Cancer Cells
Published on: June 16, 2023
Small molecule signal transduction inhibitors for the treatment of solid tumors
Alexandra Leary1, Stephen R D Johnston
1The Royal Marsden Hospital, London, UK.
Abstract:
A greater understanding of the pathogenesis of malignancy has led to the development of novel therapies designed to target aberrant molecular pathways that characterize and distinguish cancer cells from normal tissue. Small molecules are being designed to interfere with specific steps along the deregulated signaling cascade from the cytoplasmic membrane to the nucleus. Viable targets include growth factor receptors and their downstream second messengers, modulators of the cell cycle or apoptosis, regulators of protein trafficking and degradation, and transcription regulators. This review will discuss the small molecule signal transduction inhibitors in various stages of development and address the strategic issues relating to clinical trial design with these novel targeted agents.
Insights
Novel small molecule therapies target cancer's molecular pathways. This review covers signal transduction inhibitors and clinical trial strategies for these targeted cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer pathogenesis understanding drives novel therapy development.
- Targeting aberrant molecular pathways distinguishes cancer cells.
- Small molecules interfere with signaling cascades.
Purpose of the Study:
- Review small molecule signal transduction inhibitors.
- Discuss agents in various developmental stages.
- Address clinical trial design for targeted agents.
Main Methods:
- Literature review of small molecule inhibitors.
- Analysis of targeted therapy development.
- Examination of clinical trial strategies.
Main Results:
- Small molecules target diverse cellular pathways.
- Inhibitors are in multiple stages of development.
- Strategic clinical trial design is crucial.
Conclusions:
- Small molecule inhibitors represent a promising therapeutic strategy.
- Targeted agents require careful clinical trial planning.
- Advancements in understanding cancer signaling pathways are key.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Inhibition of Cdk Activity
Inhibition of CDK Activity
Tumor Immunotherapy

